Subject: Clarifications In Relation To CSL Vifor's Communications About Monofer

Dear Sir/Madam,

As you may know, the European Commission has been investigating CSL Vifor in relation to potentially misleading communications comparing Ferinject to Monofer. This investigation has been concluded without an infringement finding against CSL Vifor or admission of liability from CSL Vifor. However, CSL Vifor has agreed to a number of commitments including that CSL Vifor disseminates this communication to you.

In the context of its investigation, the European Commission raised preliminary concerns that CSL Vifor has been disseminating potentially misleading information regarding the safety of Monofer. In this regard, CSL Vifor makes the following clarifications in order to remove any possible confusion caused by its past communications about Monofer's safety:

- *There is no scientific basis to consider Ferinject to have a superior safety profile compared to Monofer.*
- *There is no basis to suggest that Monofer has a limited evidence base that would call into question its safety, which is apparent from Monofer's marketing authorisation and from the successive reviews of intravenous iron medicines by the European Medicine Agency.*
- *Pursuant to Monofer's summary of product characteristics (SmPC), which was approved by the competent regulatory authorities, Monofer is not a dextran, dextran-derived, or dextran-based product. Furthermore, Monofer does not have increased risk of hypersensitivity reactions (HSR) compared to Ferinject.*

We hope that this letter clarifies any potentially misleading past communications about Monofer.

Should you have any questions about the above or about any future communications by CSL Vifor on Monofer, please contact: HCPLetter@viforpharma.com

Sincerely,



Hervé Gisserot
General Manager CSL Vifor

Vifor Pharma Management Ltd.
Flughofstrasse 61
8152 Glattbrugg
Switzerland